Nurix Therapeutics (NRIX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- May 31, 2025
- EPS actual
- −$0.52
- EPS estimate
- −$0.72
- EPS surprise
- +27.65%
- Revenue surprise
- +151.08%
- Revenue
- $44.1M
- Revenue estimate
- $17.5M
- Reported
- Jul 9, 2025
The newest quarter in the table for Nurix Therapeutics is fiscal Q2 2025, which ended May 31, 2025, and was reported on July 9, 2025. The company posted a loss of $0.52 per share, narrower than the $0.72 loss expected, a 27.65% beat. Revenue was $44.1 million, well above the $17.5 million consensus. Compared with fiscal Q2 2024, the loss narrowed from $0.71 per share and revenue rose from $12.1 million.
Nurix lost money in all 20 quarters shown. Annual losses were $2.73 per share in fiscal 2021, $3.73 in 2022, $2.65 in 2023 and $2.89 in 2024. The first half of fiscal 2025 adds up to a loss of $1.19. Quarterly losses ranged from $0.45 per share in Q2 2023 to $1.01 in Q2 2022. Revenue is uneven, and Q2 2025's $44.1 million is the table's highest. The company beat the EPS estimate in nine of the 20 quarters.
The table holds no results after fiscal Q2 2025. In earlier years, Nurix reported fiscal Q3 between October 6 and October 14, and fiscal Q4 between late January and mid-February. Newer quarters will show whether the narrower loss and higher revenue of Q2 2025 carried on.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Jul 9, 2025 | −$0.72 | −$0.52 | +27.65% | $44.1M | SEC |
| Q1 2025 | Apr 8, 2025 | −$0.76 | −$0.67 | +12.06% | $18.5M | SEC |
| Q4 2024 | Jan 28, 2025 | −$0.69 | −$0.75 | −9.31% | $13.3M | SEC |
| Q3 2024 | Oct 11, 2024 | −$0.69 | −$0.67 | +2.57% | $12.6M | SEC |
| Q2 2024 | Jul 11, 2024 | −$0.63 | −$0.71 | −11.85% | $12.1M | SEC |
| Q1 2024 | Apr 10, 2024 | −$0.78 | −$0.76 | +2.01% | $16.6M | SEC |
| Q4 2023 | Feb 15, 2024 | −$0.50 | −$0.77 | −55.12% | $15.2M | SEC |
| Q3 2023 | Oct 12, 2023 | −$0.84 | −$0.68 | +18.90% | $18.5M | SEC |
| Q2 2023 | Jul 13, 2023 | −$0.57 | −$0.45 | +20.68% | $30.7M | SEC |
| Q1 2023 | Apr 13, 2023 | −$0.87 | −$0.75 | +13.52% | $12.7M | SEC |
| Q4 2022 | Feb 9, 2023 | −$0.78 | −$0.87 | −11.11% | $6.8M | SEC |
| Q3 2022 | Oct 6, 2022 | −$0.95 | −$0.90 | +5.05% | $10.8M | SEC |
| Q2 2022 | Jul 7, 2022 | −$0.97 | −$1.01 | −3.98% | $11.4M | SEC |
| Q1 2022 | Apr 7, 2022 | −$0.88 | −$0.95 | −8.48% | $9.6M | SEC |
| Q4 2021 | Jan 27, 2022 | −$0.68 | −$0.85 | −24.54% | $7.4M | SEC |
| Q3 2021 | Oct 14, 2021 | −$0.62 | −$0.65 | −4.60% | $10.3M | SEC |
| Q2 2021 | Jul 13, 2021 | −$0.54 | −$0.60 | −12.15% | $7.1M | SEC |
| Q1 2021 | Apr 13, 2021 | −$0.45 | −$0.63 | −39.23% | $5.0M | SEC |
| Q4 2020 | Feb 16, 2021 | −$0.53 | −$0.51 | +4.49% | $6.7M | SEC |
| Q3 2020 | Oct 14, 2020 | −$0.41 | −$0.59 | −43.03% | $4.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Nurix Therapeutics (NRIX) last report earnings?
Nurix Therapeutics last reported on Jul 9, 2025, covering fiscal Q2 2025.
Did NRIX beat earnings estimates?
Yes. Nurix Therapeutics reported EPS of −$0.52 for Q2 2025 against a −$0.72 estimate — a 27.65% beat.
How much revenue did NRIX report last quarter?
Nurix Therapeutics reported $44.1M in revenue for Q2 2025, against a consensus estimate of $17.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.